Background
Lorigerlimab (previously known as MGD019) is an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4. Lorigerlimab was designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes compared to a PD-1/CTLA-4 monoclonal antibody (mAb) combination therapy, while maintaining maximal PD-1 blockade on all PD-1-expressing cells.
Clinical Development
Please refer to our most recent corporate deck on our Events & Presentations page for the latest clinical information available on lorigerlimab.
Our Rights
MacroGenics retains global rights to lorigerlimab.
Clinical Trials
- Lorigerlimab Phase 2 LINNET study in PROC or CCGC (NCT06730347)
- Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) (NCT05475171)
Presentations & Publications
Relevant Publications and Presentations can be found at https://www.macrogenics.com/publications/.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.